Onderneming Zealand Pharma A/S Nasdaq
Aandelen
ZEAL
US98920Y3045
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 270
Verkoop per activiteit
DKK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Peptide-based Medicines
100,0
%
| 104 | 100,0 % | 343 | 100,0 % | +229,65% |
Verkoop per regio
DKK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Germany
85,9
%
| - | - | 294 509 | 85,9 % | - |
Denmark
12,9
%
| 35 | 33,7 % | 44 185 | 12,9 % | +126.142,86% |
United States
1,2
%
| 69 | 66,3 % | 4 094 | 1,2 % | +5.833,33% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 50 | 01-01-10 | |
Director of Finance/CFO | - | 01-11-22 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 01-03-18 |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 62 | 02-06-22 |
Director/Board Member | 57 | - | |
Anna Krassowska
IRC | Investor Relations Contact | - | - |
Ravinder Chahil
LAW | General Counsel | 56 | - |
Human Resources Officer | 39 | 01-01-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 04-04-19 |
Chairman | 69 | 01-01-15 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 19-04-18 |
Director/Board Member | 58 | 04-04-19 | |
Director/Board Member | 65 | 04-04-19 | |
Director/Board Member | 57 | - | |
Anneline Nansen
BRD | Director/Board Member | 55 | 01-09-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 62 626 184 | 62 176 860 ( 99,28 %) | 351 307 ( 0,5610 %) | 99,28 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
ZEALAND PHARMA A/S 0.60% | 373 134 | 0.60% | 33 861 213 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |